- Home
- AIRI vs MTVA Comparison
AIRI vs MTVA Comparison
Compare AIRI & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- MTVA
- Stock Information
- Founded
- AIRI 1979
- MTVA 2014
- Country
- AIRI United States
- MTVA United States
- Employees
- AIRI N/A
- MTVA N/A
- Industry
- AIRI Military/Government/Technical
- MTVA
- Sector
- AIRI Industrials
- MTVA
- Exchange
- AIRI Nasdaq
- MTVA NYSE
- Market Cap
- AIRI 13.4M
- MTVA 14.3M
- IPO Year
- AIRI N/A
- MTVA N/A
- Fundamental
- Price
- AIRI $3.49
- MTVA $0.67
- Analyst Decision
- AIRI
- MTVA Strong Buy
- Analyst Count
- AIRI 0
- MTVA 2
- Target Price
- AIRI N/A
- MTVA $7.50
- AVG Volume (30 Days)
- AIRI 1.5M
- MTVA 67.0K
- Earning Date
- AIRI 08-13-2025
- MTVA 08-13-2025
- Dividend Yield
- AIRI N/A
- MTVA N/A
- EPS Growth
- AIRI N/A
- MTVA N/A
- EPS
- AIRI N/A
- MTVA N/A
- Revenue
- AIRI $53,182,000.00
- MTVA N/A
- Revenue This Year
- AIRI $5.59
- MTVA N/A
- Revenue Next Year
- AIRI $5.00
- MTVA N/A
- P/E Ratio
- AIRI N/A
- MTVA N/A
- Revenue Growth
- AIRI 0.29
- MTVA N/A
- 52 Week Low
- AIRI $3.00
- MTVA $0.60
- 52 Week High
- AIRI $9.44
- MTVA $4.81
- Technical
- Relative Strength Index (RSI)
- AIRI 52.15
- MTVA N/A
- Support Level
- AIRI $3.31
- MTVA N/A
- Resistance Level
- AIRI $3.58
- MTVA N/A
- Average True Range (ATR)
- AIRI 0.17
- MTVA 0.00
- MACD
- AIRI 0.02
- MTVA 0.00
- Stochastic Oscillator
- AIRI 26.88
- MTVA 0.00
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.